G to C transition at position -173 of MIF gene of the recipient is associated with reduced relapse rates after allogeneic stem cell transplantation

Cytokine

Volumn 48, Issue 3, 2009, Pages 218-225

  Chang, Ya Yi ^a   Greinix, Hildegard T ^b   Dickinson, Anne M ^c   Wolff, Daniel ^a,d   Jackson, Graham H ^c   Andreesen, Reinhard ^a   Holler, Ernst ^a   Hildebrandt, Gerhard C ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Allogeneic; MIF; Polymorphism; Relapse; Stem cell transplantation

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTOSINE; FLUDARABINE; GUANINE; MACROPHAGE MIGRATION INHIBITION FACTOR; MELPHALAN; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; DONOR; DRUG MEGADOSE; FEMALE; GENOTYPE; GRAFT RECIPIENT; GRAFT VERSUS LEUKEMIA EFFECT; GRAFT VERSUS LYMPHOMA EFFECT; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOFIBROSIS; OSTEOSCLEROSIS; OVERALL SURVIVAL; PATIENT COUNSELING; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SURVIVAL RATE; SURVIVAL TIME; T CELL DEPLETION;

ADOLESCENT; ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECURRENCE; STEM CELL TRANSPLANTATION; YOUNG ADULT;

EID: 70350029055     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.07.012     Document Type: Article

References (60)

1. Ferrara J.L., and Deeg H.J. Graft-versus-host disease. N Engl J Med 324 10 (1991) 667-674
2. Higman M.A., and Vogelsang G.B. Chronic graft versus host disease. Br J Haematol 125 4 (2004) 435-454
3. Shlomchik W.D., Couzens M.S., Tang C.B., McNiff J., Robert M.E., Liu J., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285 5426 (1999) 412-415
4. Teshima T., Ordemann R., Reddy P., Gagin S., Liu C., Cooke K.R., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 8 6 (2002) 575-581
5. Murai M., Yoneyama H., Ezaki T., Suematsu M., Terashima Y., Harada A., et al. Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol 4 2 (2003) 154-160
6. Schmaltz C., Alpdogan O., Horndasch K.J., Muriglan S.J., Kappel B.J., Teshima T., et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 97 9 (2001) 2886-2895
7. Schmaltz C., Alpdogan O., Kappel B.J., Muriglan S.J., Rotolo J.A., Ongchin J., et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med 8 12 (2002) 1433-1437
8. Bloom B.R., and Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153 731 (1966) 80-82
9. David J.R. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 56 1 (1966) 72-77
10. Calandra T., Bernhagen J., Metz C.N., Spiegel L.A., Bacher M., Donnelly T., et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377 6544 (1995) 68-71
11. Lue H., Kleemann R., Calandra T., Roger T., and Bernhagen J. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 4 4 (2002) 449-460
12. Baugh J.A., and Bucala R. Macrophage migration inhibitory factor. Crit Care Med 30 1 Suppl. (2002) S27-S35
13. Bernhagen J., Calandra T., Mitchell R.A., Martin S.B., Tracey K.J., Voelter W., et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365 6448 (1993) 756-759
14. Calandra T., Bernhagen J., Mitchell R.A., and Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179 6 (1994) 1895-1902
15. Bacher M., Metz C.N., Calandra T., Mayer K., Chesney J., Lohoff M., et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93 15 (1996) 7849-7854
16. Bozza M., Satoskar A.R., Lin G., Lu B., Humbles A.A., Gerard C., et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 189 2 (1999) 341-346
17. Calandra T., Echtenacher B., Roy D.L., Pugin J., Metz C.N., Hultner L., et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6 2 (2000) 164-170
18. Donnelly S.C., Haslett C., Reid P.T., Grant I.S., Wallace W.A., Metz C.N., et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 3 3 (1997) 320-323
19. Morand E.F., Bucala R., and Leech M. Macrophage migration inhibitory factor: an emerging therapeutic target in rheumatoid arthritis. Arthritis Rheum 48 2 (2003) 291-299
20. Selvi E., Tripodi S.A., Catenaccio M., Lorenzini S., Chindamo D., Manganelli S., et al. Expression of macrophage migration inhibitory factor in diffuse systemic sclerosis. Ann Rheum Dis 62 5 (2003) 460-464
21. Lo J.W., Leung A.Y., Huang X.R., Lie A.K., Metz C., Bucala R., et al. Macrophage migratory inhibitory factor (MIF) expression in acute graft-versus-host disease (GVHD) in allogeneic hemopoietic stem cell transplant recipients. Bone Marrow Transplant 30 6 (2002) 375-380
22. Toubai T., Shono Y., Nishihira J., Ibata M., Suigita J., Kato N., et al. Serum macrophage migration inhibitory factor (MIF) levels after allogeneic hematopoietic stem cell transplantation. Int J Lab Hematol 31 2 (2009) 161-168
23. Weiser W.Y., Temple P.A., Witek-Giannotti J.S., Remold H.G., Clark S.C., and David J.R. Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc Natl Acad Sci USA 86 19 (1989) 7522-7526
24. Budarf M., McDonald T., Sellinger B., Kozak C., Graham C., and Wistow G. Localization of the human gene for macrophage migration inhibitory factor (MIF) to chromosome 22q11.2. Genomics 39 2 (1997) 235-236
25. Gao L., Flores C., Fan-Ma S., Miller E.J., Moitra J., Moreno L., et al. Macrophage migration inhibitory factor in acute lung injury: expression, biomarker, and associations. Transl Res 150 1 (2007) 18-29
26. Donn R., Alourfi Z., De Benedetti F., Meazza C., Zeggini E., Lunt M., et al. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 46 9 (2002) 2402-2409
27. Donn R.P., Shelley E., Ollier W.E., and Thomson W. A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 44 8 (2001) 1782-1785
28. Dambacher J., Staudinger T., Seiderer J., Sisic Z., Schnitzler F., Pfennig S., et al. Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease. Inflamm Bowel Dis 13 1 (2007) 71-82
29. Glucksberg H., Storb R., Fefer A., Buckner C., Neiman P., Clift R., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 18 (1974) 295-304
30. Team RDC. R: a language and environment for statistical computing. R Found Stat Comput 2008;ISBN 3-900051-07-0.
31. Amoli M.M., Donn R.P., Thomson W., Hajeer A.H., Garcia-Porrua C., Lueiro M., et al. Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum. J Rheumatol 29 8 (2002) 1671-1673
32. Miterski B., Drynda S., Boschow G., Klein W., Oppermann J., Kekow J., et al. Complex genetic predisposition in adult and juvenile rheumatoid arthritis. BMC Genet 5 (2004) 2
33. Donn R.P., and Ray D.W. Macrophage migration inhibitory factor: molecular, cellular and genetic aspects of a key neuroendocrine molecule. J Endocrinol 182 1 (2004) 1-9
34. Reddy P., Maeda Y., Liu C., Krijanovski O.I., Korngold R., and Ferrara J.L. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med 11 11 (2005) 1244-1249
35. Morelli A.E., Zahorchak A.F., Larregina A.T., Colvin B.L., Logar A.J., Takayama T., et al. Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood 98 5 (2001) 1512-1523
36. Murakami H., Akbar S.M., Matsui H., Horiike N., and Onji M. Macrophage migration inhibitory factor activates antigen-presenting dendritic cells and induces inflammatory cytokines in ulcerative colitis. Clin Exp Immunol 128 3 (2002) 504-510
37. Middleton P.G., Taylor P.R., Jackson G., Proctor S.J., and Dickinson A.M. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood 92 10 (1998) 3943-3948
38. Takahashi H., Furukawa T., Hashimoto S., Suzuki N., Kuroha T., Yamazaki F., et al. Contribution of TNF-alpha and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation. Bone Marrow Transplant 26 12 (2000) 1317-1323
39. Cavet J., Middleton P.G., Segall M., Noreen H., Davies S.M., and Dickinson A.M. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood 94 11 (1999) 3941-3946
40. Cavet J., Dickinson A.M., Norden J., Taylor P.R., Jackson G.H., and Middleton P.G. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 98 5 (2001) 1594-1600
41. Hagemann T., Wilson J., Kulbe H., Li N.F., Leinster D.A., Charles K., et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 175 2 (2005) 1197-1205
42. Taylor III J.A., Kuchel G.A., Hegde P., Voznesensky O.S., Claffey K., Tsimikas J., et al. Null mutation for macrophage migration inhibitory factor (MIF) is associated with less aggressive bladder cancer in mice. BMC Cancer 7 (2007) 135
43. Meyer-Siegler K.L., Vera P.L., Iczkowski K.A., Bifulco C., Lee A., Gregersen P.K., et al. Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes Immun 8 8 (2007) 646-652
44. Meyer-Siegler K.L., Iczkowski K.A., Leng L., Bucala R., and Vera P.L. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol 177 12 (2006) 8730-8739
45. Chesney J., Metz C., Bacher M., Peng T., Meinhardt A., and Bucala R. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med 5 3 (1999) 181-191
46. Binsky I., Haran M., Starlets D., Gore Y., Lantner F., Harpaz N., et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci USA 104 33 (2007) 13408-13413
47. Talos F., Mena P., Fingerle-Rowson G., Moll U., and Petrenko O. MIF loss impairs Myc-induced lymphomagenesis. Cell Death Differ 12 10 (2005) 1319-1328
48. Kobel M., Kalloger S.E., Boyd N., McKinney S., Mehl E., Palmer C., et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5 12 (2008) e232
49. Ding G.X., Zhou S.Q., Xu Z., Feng N.H., Song N.H., Wang X.J., et al. The association between MIF-173 G > C polymorphism and prostate cancer in southern Chinese. J Surg Oncol 100 2 (2009) 106-110
50. Arisawa T., Tahara T., Shibata T., Nagasaka M., Nakamura M., Kamiya Y., et al. Functional promoter polymorphisms of the macrophage migration inhibitory factor gene in gastric carcinogenesis. Oncol Rep 19 1 (2008) 223-228
51. Toubai T., Tanaka J., Nishihira J., Ohkawara T., Hirate D., Kondo N., et al. Effect of macrophage migration inhibitory factor (MIF) on acute graft-versus-host disease in a murine model of allogeneic stem cell transplantation. Transpl Immunol 16 2 (2006) 117-124
52. Barnes D., Corp M., Loutit J., and Neal F. Treatment of murine leukaemia with X-rays and homologous bone marrow: preliminary communication. Br Med J 2 (1956) 626-630
53. Barnes D., and Loutit J. Treatment of murine leukaemia with X-rays and homologous bone marrow. Br J Haematol 3 (1957) 241-252
54. Edinger M., Hoffmann P., Ermann J., Drago K., Fathman C.G., Strober S., et al. CD4(+)CD25(+) regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9 9 (2003) 1144-1150
55. Choi S.W., Hildebrandt G.C., Olkiewicz K.M., Hanauer D.A., Chaudhary M.N., Silva I.A., et al. CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation. Blood 110 9 (2007) 3447-3455
56. Reddy P., Maeda Y., Hotary K., Liu C., Reznikov L.L., Dinarello C.A., et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 101 11 (2004) 3921-3926
57. Anderson B.E., McNiff J.M., Jain D., Blazar B.R., Shlomchik W.D., and Shlomchik M.J. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood 105 5 (2005) 2227-2234
58. Chakraverty R., and Sykes M. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood 110 1 (2007) 9-17
59. Ohkawara T., Takeda H., Miyashita K., Nishiwaki M., Nakayama T., Taniguchi M., et al. Regulation of toll-like receptor 4 expression in mouse colon by macrophage migration inhibitory factor. Histochem Cell Biol 125 5 (2006) 575-582
60. Fukushima T., Nishihira J., Yoshiki T., Iwabuchi K., Iwabuchi C., Yamasaki Y., et al. Evidence of dual function of macrophage migration inhibitory factor relevant to tumor progression and regression. Int J Mol Med 16 1 (2005) 119-126